Tuesday, November 8, 2011

Monosodium Luminol could be useful Friedreich’s Ataxia.

Bach Pharma, Inc. and Destum Partners, Inc.

NORTH ANDOVER, Massachusetts – October 31, 2011,

"Approvals are in place to annually treat over a half million cancer patients in the CIS countries alone, a very attractive market opportunity especially for an Eastern European partner. In CNS related diseases, GVT® is the subject of a phase I/II clinical study to treat ataxia-telangiectasia (A-T), a rare childhood genetic disorder, which currently has no effective treatment and leads to early complications of aging and death among its young patients. This study demonstrates strong pre-clinical support for its use in other CNS and/or Orphan diseases such as Parkinson’s, Amyotrophic Lateral Sclerosis (ALS) and Friedreich’s Ataxia."

"The Company intends to focus its clinical efforts through sponsored research!!."